NeoPharm CO. LTD (092730) — Cash Flow Reinvestment Rate
NeoPharm CO. LTD (092730) has a Cash Flow Reinvestment Rate of 0.25x as of September 2025, reinvesting ₩1.45 Billion (capex ₩446.60 Million plus investments ₩-1.00 Billion) from operating cash flow of ₩5.88 Billion. Check 092730 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
NeoPharm CO. LTD Cash Flow Reinvestment Rate (2012–2024)
Historical reinvestment intensity for NeoPharm CO. LTD across 11 annual periods. Explore investment intensity of NeoPharm CO. LTD to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for NeoPharm CO. LTD (2012–2024)
Year-by-year capital reinvestment analysis for NeoPharm CO. LTD. For live market cap and broader valuation context, see market value of NeoPharm CO. LTD.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.50x | ₩9.30 Billion | ₩18.63 Billion | ₩3.08 Billion | ▼ -68.8% |
| 2023 | 1.60x | ₩37.18 Billion | ₩23.26 Billion | ₩20.83 Billion | ▲ +202.2% |
| 2022 | 0.53x | ₩9.61 Billion | ₩18.16 Billion | ₩806.43 Million | ▼ -29.7% |
| 2021 | 0.75x | ₩16.32 Billion | ₩21.68 Billion | ₩320.11 Million | ▲ +199.9% |
| 2020 | 0.25x | ₩4.29 Billion | ₩17.07 Billion | ₩285.62 Million | ▼ -90.7% |
| 2019 | 2.70x | ₩51.90 Billion | ₩19.22 Billion | ₩5.90 Billion | ▲ +398.5% |
| 2018 | 0.54x | ₩8.76 Billion | ₩16.18 Billion | ₩1.94 Billion | ▼ -48.2% |
| 2017 | 1.05x | ₩11.13 Billion | ₩10.65 Billion | ₩884.71 Million | ▲ +17.2% |
| 2016 | 0.89x | ₩8.17 Billion | ₩9.16 Billion | ₩1.40 Billion | ▲ +133.3% |
| 2015 | 0.38x | ₩2.33 Billion | ₩6.09 Billion | ₩786.89 Million | ▼ -81.5% |
| 2012 | 2.06x | ₩1.16 Billion | ₩564.34 Million | ₩172.47 Million | — |